Descartes-11 in Multiple Myeloma

Overview

This Phase I study will test the safety and anti-myeloma activity of ascending doses of Descartes-11 (autologous CD8+ T-cells expressing an anti-BCMA chimeric antigen receptor) in eligible patients with active multiple myeloma.

SparkCures ID 1010
Trial Phase Phase 1
Enrollment 18 Patients
Treatments
Trial Sponsors
  • Cartesian Therapeutics
NCT Identifier

NCT03994705

Am I Eligible?

The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.

The following criteria is provided for health care professionals.

Inclusion Criteria:

  • Active multiple myeloma that is refractory after at least 2 prior lines of therapy;
  • measurable disease;
  • adequate vital organ function; and
  • no active infection.

US Trial Locations

Accepting Patients

The following is a listing of trial locations that are open and accepting patients.

Center for Cancer and Blood Disorders

Bethesda, MD

Not Currently Accepting Patients

The following is a listing of trial locations that are not currently open and accepting patients.

Verified Medical College of Wisconsin<br />Froedtert Hospital

SparkCures Verified Accurate, up-to-date information. Learn more

Maryland
Center for Cancer and Blood Disorders

Bethesda, MD

Wisconsin
Verified Medical College of Wisconsin<br />Froedtert Hospital

SparkCures Verified Accurate, up-to-date information. Learn more

Resources

There are no resources, links or videos to display for this clinical trial.